Highlights from the 1st International Workshop on HIV and Hepatitis Co-infection

REFERENCES

• Nelson M, Browne R, Asboe D, Gilleece Y, Atkins M, Gazzard B. Increasing incidence of acute hepatitis C in HIV-positive men secondary to sexual transmission, epide-miology and treatment. In: Programs and abstracts from the 9th European AIDS Conference; October 25–29, 2003; Warsaw, Poland. F12/3.
   Google Scholar
• Braitstein P, et al. Attenuated absolute but preserved CD4 fraction response to antiretroviral therapy among previ-ously naive HIV/HCV coinfected adults. In: Programs and abstracts from the 1st International Workshop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI08.
   Google Scholar
• Wong J, et al. Impact of HAART on the prognosis of HIV-HCV co-infection. In: Programs and abstracts from the 1st International Workshop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI31.
   Google Scholar
• Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection. Lancet. 2003; 362:1708–1713.
   PubMed Web of Science ®Google Scholar
• Bonacini M, Louie S, Bzowej N, Wohl A. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18:2039–2046.
   PubMed Web of Science ®Google Scholar
• Benhamou Y, DeMartinio V, Bochet M, et al. Factors affect-ing liver fibrosis in HIV and hepatitis C virus coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001;34:283–287.
   PubMed Web of Science ®Google Scholar
• Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS. 2004;18:767–774.
   PubMed Web of Science ®Google Scholar
• Marine-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibro-sis in HIV/hepatitis C virus co-infected patients. AIDS. 2004;18:2163–2170.
   PubMed Web of Science ®Google Scholar
• De Ledinghen V, et al. FibroScan® is a new non-invasive method for the detection of cirrhosis and its complications in patients with chronic liver diseases. Results of a pro-spective study in 711 patients. In: Programs and abstracts from the 1st International Workshop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Nether-lands. Abstract CI39.
   Google Scholar
• Imbert-Bismut F, Messous D, Thibaut V, Myers RB, Piton A, Thabut D, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med. 2004;42:323–333.
   PubMed Web of Science ®Google Scholar
• Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp HepatoL 2004;3:8.
   PubMedGoogle Scholar
• Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion. 2003;43:788–798.
   PubMed Web of Science ®Google Scholar
• Kimura T, Rokuhara A, Matsumoto A, Yagi S, Tanaka E, Kiyosawa K, et al. New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation be-tween levels of HBcAg and HBV DNA. J Clin Microbiol. 2003;41:1901–1906.
   PubMed Web of Science ®Google Scholar
• Kohmoto M, Enomoto M, Yano Y, Otani S, Minamitani S, Tamori A, et al. Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: comparison with three other assays. Hepatol Res. 2003;26:125–133.
   PubMed Web of Science ®Google Scholar
• Bonacini M, et al. Presence of multiple HCV genotypes and response to interferon-ribavirin therapy in HIV/HCV co-in-fected patients. In: Programs and abstracts from the 1st International Workshop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI29.
   Google Scholar
• Perronne C, et al. A randomized controlled trial of pegylated-interferon alfa-2b plus ribavirin vs interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV-infected patients (ARS HCO2 RIBVIC). In: Programs and abstracts from the 1st International Work-shop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI37.
   Google Scholar
• Soriano V, et al. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to geno-type 4. In: Programs and abstracts from the 1st Interna-tional Workshop on HIV and Hepatitis Co-infection; De-cember 2–4; Amsterdam, The Netherlands. Abstract CI03.
   Google Scholar
• Sarmento-Castro R, et al. Moderate dose of peginterferon alfa-2b in combination with ribavirin in the treatment of HCV patients with or without HIV. In: Programs and ab-stracts from the 1st International Workshop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI01.
   Google Scholar
• Angeli E, et al. Usefulness of 8-weeks early virological response (EVR) to predict sustained response to PEG-IFN alfa-2b plus RBV: results from an Italian, multicentre, ran-domized trial. In: Programs and abstracts from the 1st International Workshop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CIS.
   Google Scholar
• Ramos B, et al. Early HCV-RNA clearance in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. In: Programs and abstracts from the 1st Interna-tional Workshop on HIV and Hepatitis Co-infection; De-cember 2–4; Amsterdam, The Netherlands. Abstract CI14.
   Google Scholar
• Vogel M, et al. Pegylated interferon/ribavirin for the treat-ment of acute hepatitis C in HIV-coinfected patients. In: Programs and abstracts from the 1st International Work-shop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI09.
   Google Scholar
• Dominguez S, et al. Evaluation of a 24-week pegylated interferon and ribavirin therapy in HIV patients with acute HCV. In: Programs and abstracts from the 1st International Workshop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI33.
   Google Scholar
• Schwarze-Zander C, et al. GB virus-C clearance in HIV/HCV co-infected patients receiving interferon and ribavirin treatment. In: Programs and abstracts from the 1st Interna-tional Workshop on HIV and Hepatitis Co-infection; De-cember 2–4; Amsterdam, The Netherlands. Abstract CI22.
   Google Scholar
• Schildgen O, et al. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. In: Programs and abstracts from the 1st International Workshop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI26.
   Google Scholar
• Puoti M, et al. The management of hepatitis B virus (HBV)/ HIV-1 co-infected patients starting their first HAART regi-men. Treating two infections at the price of one drug? In: Programs and abstracts from the 1st International Work-shop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI32.
   Google Scholar
• Mauss S, et al. Is tenofovir plus lamivudine superior to tenofovir monotherapy in patients with HBV/HIV co-infec-tion? In: Programs and abstracts from the 1st International Workshop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI36.
   Google Scholar
• Bartholomeusz A, et al. Characterization of lamivudine re-sistant hepatitis B virus (HBV) mutations in HIV-HBV co-infected individuals. In: Programs and abstracts from the 1st International Workshop on HIV and Hepatitis Co-infec-tion; December 2–4; Amsterdam, The Netherlands. Ab-stract CI41.
   Google Scholar
• Postel N, et al. Anti-HBV vaccination in HIV-infection: suc-cessful only with CD4 cell count > 5004 combined with a viral load below 1,000 cps/ml. In: Programs and abstracts from the 1st International Workshop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Nether-lands. Abstract CI25.
   Google Scholar
• Rend6n A, et al. Effect of nucleoside analogues on ribavirin plasma concentrations in H IV/H CV co-infected patients. In: Programs and abstracts from the 1st International Work-shop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI12.
   Google Scholar
• Rend6n A, et al. Ribavirin plasma concentrations predict early virological response as well as anemia in anti-hepati-tis C therapy. In: Programs and abstracts from the 1st International Workshop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI18.
   Google Scholar
• Dominguez S, et al. The HEPADOSE Study: differences of protease inhibitors and non-nucleoside analogue plasma concentrations between HIV/HCV and HIV patients. In: Programs and abstracts from the 1st International Work-shop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI34.
   Google Scholar
• Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al. Hepatocellular carcinoma in HIV-infected pa-tients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18:2285–2293.
   PubMed Web of Science ®Google Scholar
• Vogel M, et al. Orthotopic liver transplantation (OLT)) in HIV-positive patients: outcome of 10 patients from the Bonn cohort. In: Programs and abstracts from the 1st International Workshop on HIV and Hepatitis Co-infection; December 2–4; Amsterdam, The Netherlands. Abstract CI16.
   Google Scholar